Seung-Jung Recreation area, M vasodilator effects .D., Duk-Woo Recreation area, M.D., Young-Hak Kim, M.D., Soo-Jin Kang, M.D., Seung-Whan Lee, M.D., Cheol Whan Lee, M.D., Ki-Hoon Han, M.D., Seong-Wook Park, M.D., Sung-Cheol Yun, Ph.D., Sang-Gon Lee, M.D., Seung-Woon Rha, M.D., In-Whan Seong, M.D., Myung-Ho Jeong, M.D., Seung-Ho Hur, M.D., Nae-Hee Lee, M.D., Junghan Yoon, M.D., Joo-Adolescent Yang, M.D., Bong-Ki Lee, M.D., Young-Jin Choi, M.D., Wook-Sung Chung, M.D., Do-Sunlight Lim, M.D., Sang-Sig Cheong, M.D., Kee-Sik Kim, M.D., Jei Keon Chae, M.D., Deuk-Young Nah, M.D., Doo-Soo Jeon, M.D., Ki Bae Seung, M.D., Jae-Sik Jang, M.D., Hun Sik Recreation area, M.D., and Keun Lee, M.D.: Duration of Dual Antiplatelet Therapy after Implantation of Drug-Eluting Stents Several pivotal clinical trials have shown that the usage of drug-eluting coronary stents is certainly associated with significant reductions in the risks of restenosis and need for target-lesion revascularization, in comparison with use of bare-metallic coronary stents.1 Based on the total results of the trials, drug-eluting stents have been useful for percutaneous coronary intervention in clinical practice widely.2 However, some longer-term research have shown that drug-eluting stents, as compared with bare-steel stents, are connected with increased rates of late stent thrombosis, death, or myocardial infarction.3,4 It has been proposed that the occurrence of late clinical events may be because of delayed arterial healing following the implantation of drug-eluting stents.5 Early discontinuation of dual antiplatelet therapy has been defined as a risk factor for late stent thrombosis in patients with drug-eluting stents.6,7 Current PCI recommendations advise that clopidogrel, at a dose of 75 mg daily, should be provided for at least 12 months after implantation of drug-eluting stents if patients are not at high risk for bleeding.
Given the fixed-time plan for glucose measurement, a discrete period proportional-odds model was useful for the incidence of diabetes. We also carried out predefined analyses of the components of the composite cardiovascular outcomes, time and energy to death from any trigger, time to cardiovascular-related hospitalization, indexes of hyperglycemia, and bodyweight. The chance of interaction between nateglinide and valsartan was tested for every outcome reported. The consequences of study treatment had been evaluated in prespecified subgroups.17 We compared baseline characteristics, safety, and other trial assessments using summary statistics. Results Study Patients Of 43,502 patients who underwent screening, 9518 were assigned to treatment randomly. After randomization, 212 sufferers were excluded from the evaluation, since 10 sites had been closed because of deficiencies in meeting Great Clinical Practice recommendations, which left 9306 patients who could possibly be evaluated .